Browsing Tag
Abbott Laboratories
24 posts
Abbott pays $670m to settle Gill and 2,000 NEC claims, $70m above one judgment
Abbott has agreed to pay about $670 million to resolve the Gill verdict and claims involving roughly 2,000 other infants, substantially reducing one litigation block while leaving a much larger pool of NEC claims outstanding.
Heart ablation is moving beyond heat and cold, and the medtech race is getting much bigger
Pulsed field ablation is changing atrial fibrillation treatment by using extremely short electrical pulses to disrupt targeted cardiac cells instead of relying primarily on heat or freezing. Boston Scientific, Medtronic, Abbott Laboratories and Johnson & Johnson now compete across multiple FDA-approved PFA platforms, while new trials are pushing the technology into persistent atrial fibrillation, broader lesion sets and potentially earlier treatment.
Leadless pacemakers: How tiny implants inside the heart are challenging cardiac leads
Leadless pacemakers are moving beyond a niche alternative for selected patients. Abbott’s AVEIR DR can pace both the right atrium and right ventricle using two communicating intracardiac devices, while Medtronic is extending battery life and Boston Scientific is developing a wireless pacemaker-defibrillator system. The technology removes the chest pocket and transvenous leads that create important complications in conventional pacing, but retrieval, long-term device accumulation, patient selection and the limits of current pacing modes still stand between leadless systems and wholesale replacement of traditional pacemakers.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
Abbott adds colorectal cancer blood test to Cologuard portfolio after Freenome FDA win
Freenome wins FDA approval for SimpleScreen CRC, triggering a $100 million Abbott payment and setting up a fall U.S. launch.
Abbott (ABT) stock surges 12% as Q2 earnings beat lifts 2026 EPS outlook to $5.45-$5.60
Abbott shares headed for their strongest daily gain in 24 years after the healthcare group beat second-quarter expectations and raised its adjusted earnings forecast.
Catheter Precision (VTAK) rallies 122% on new patents and Flyte 1,000 user milestone
Catheter Precision (VTAK) rallies 122% as two new patents and Flyte hits 1,000 users boost pivot story. Going concern warning still shadows the rally.
Saluda Medical wins CAP24 FDA approval as ASX:SLD shares rally 22%
Discover how Saluda Medical’s CAP24 FDA approval may expand Evoke adoption, reshape SCS competition and test ASX’s execution. Read the analysis in full.
Why does Danaher (DHR) completing the Masimo acquisition matter for diagnostics and patient monitoring?
Find out how Danaher’s $9.9bn Masimo acquisition could reshape DHR’s diagnostics growth, medtech competition and investor sentiment.
Insulet Omnipod 6 data puts PODD back in focus as automated insulin delivery moves toward type 2 diabetes
Read how Insulet Omnipod 6 data could reshape automated insulin delivery, type 2 diabetes care and PODD stock sentiment. Find out what changes next in 2026.